Exclusive Summary

• Unique Dual-channel CCB mechanism: Delivers simultaneous blood pressure control and renal protection without reflex tachycardia or severe pedal edema, serving as a premium upgrade to Amlodipine.
• Massive target patient population: Accurately covers the core needs of over 1.2 billion hypertensive patients globally, particularly ideal for those with comorbid diabetes or chronic kidney disease (CKD).
• Expansive potential in emerging markets: As the innovator drug was not heavily marketed in the US/EU, vast distribution and generic penetration opportunities remain untapped across Southeast Asia, LATAM, MENA, and Africa.
• Exceptional supply chain profitability: Backed by China's mature integrated API-to-formulation manufacturing, highly competitive pricing guarantees lucrative margin structures for regional distributors.